Ultragenyx Pharmaceutical Inc. (RARE)
Company Info
Highlights
$3.65B
-$6.29
-0.24
$451.40M
$383.34M
-$323.47M
$29.59 - $60.37
$91.80
6.02%
5.95
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Ultragenyx Pharmaceutical Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Ultragenyx Pharmaceutical Inc. (RARE) returned -16.54% year-to-date (YTD) and -14.82% over the past 12 months. Over the past 10 years, RARE returned -6.98% annually, underperforming the S&P 500 benchmark at 10.45%.
RARE
-16.54%
3.54%
-30.28%
-14.82%
-11.30%
-6.98%
^GSPC (Benchmark)
-3.77%
3.72%
-5.60%
8.55%
14.11%
10.45%
Monthly Returns
The table below presents the monthly returns of RARE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 2.28% | -0.26% | -15.63% | 7.65% | -9.93% | -16.54% | |||||||
| 2024 | -7.76% | 17.25% | -9.73% | -8.89% | -5.64% | 2.39% | 9.54% | 26.12% | -2.17% | -8.21% | -6.59% | -11.67% | -12.02% |
| 2023 | -2.16% | -1.85% | -9.87% | 8.90% | 13.03% | -6.54% | -6.53% | -14.68% | -3.10% | -0.70% | 9.75% | 23.09% | 3.22% |
| 2022 | -16.84% | -3.73% | 7.87% | -2.66% | -33.65% | 27.21% | -10.69% | -10.49% | -13.17% | -2.29% | -10.28% | 27.63% | -44.90% |
| 2021 | 0.12% | 2.13% | -19.56% | -1.95% | -8.89% | -6.25% | -16.28% | 20.62% | -6.34% | -6.95% | -10.36% | 11.78% | -39.25% |
| 2020 | 23.04% | 6.72% | -20.77% | 36.01% | 13.29% | 14.26% | -0.08% | 8.83% | -3.37% | 22.28% | 17.95% | 16.78% | 224.12% |
| 2019 | 13.43% | 30.05% | 8.14% | -4.84% | -16.77% | 15.60% | -5.10% | -9.61% | -21.46% | -6.17% | -1.22% | 7.72% | -1.77% |
| 2018 | 15.03% | -10.38% | 6.65% | -0.29% | 43.98% | 5.01% | 2.91% | 7.10% | -9.90% | -36.53% | 10.77% | -18.99% | -6.25% |
| 2017 | 6.68% | 13.42% | -20.33% | -5.00% | -16.37% | 15.34% | 6.78% | -13.96% | -6.66% | -13.46% | 9.55% | -8.14% | -34.03% |
| 2016 | -49.95% | 8.62% | 3.80% | 6.81% | 8.10% | -33.09% | 29.38% | 4.17% | 7.62% | -16.85% | 32.72% | -10.19% | -37.32% |
| 2015 | 32.41% | -6.59% | 14.41% | -9.12% | 54.17% | 17.69% | 18.11% | -7.70% | -13.72% | 3.16% | -1.04% | 14.10% | 155.65% |
| 2014 | 31.98% | -12.32% | -20.68% | -3.15% | 19.52% | -2.65% | 22.11% | 6.07% | -16.94% | -7.28% | 0.67% | 3.86% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of RARE is 33, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Ultragenyx Pharmaceutical Inc. (RARE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Ultragenyx Pharmaceutical Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Ultragenyx Pharmaceutical Inc. was 82.49%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Ultragenyx Pharmaceutical Inc. drawdown is 80.21%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -82.49% | Dec 24, 2020 | 1076 | Apr 8, 2025 | — | — | — |
| -74.79% | Jul 21, 2015 | 1172 | Mar 16, 2020 | 186 | Dec 8, 2020 | 1358 |
| -49.59% | Mar 13, 2014 | 48 | May 20, 2014 | 232 | Apr 22, 2015 | 280 |
| -18.98% | Apr 27, 2015 | 4 | Apr 30, 2015 | 8 | May 12, 2015 | 12 |
| -14.6% | Feb 3, 2014 | 3 | Feb 5, 2014 | 5 | Feb 12, 2014 | 8 |
Volatility
Volatility Chart
The current Ultragenyx Pharmaceutical Inc. volatility is 15.93%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Ultragenyx Pharmaceutical Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Ultragenyx Pharmaceutical Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -9.4%.
Valuation
The Valuation section provides an overview of how Ultragenyx Pharmaceutical Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for RARE compared to other companies in the Biotechnology industry. RARE currently has a PEG ratio of -0.2. This PEG ratio is negative, which typically signals that the company's earnings are expected to decline. A negative PEG is not considered meaningful for valuation purposes.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for RARE relative to other companies in the Biotechnology industry. Currently, RARE has a P/S ratio of 6.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for RARE in comparison with other companies in the Biotechnology industry. Currently, RARE has a P/B value of 14.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |